Cellectis, CiRA Partner on Induced Pluripotent Stem Cell Technology Development

The collaboration will combine Cellectis' genome engineering technology with CiRA's iPS technology "to rationally engineer the genome of these cells in order to provide better control over their behavior," the two companies said.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories